- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07553559
Evaluación de una herramienta de apoyo diagnóstico basada en inteligencia artificial para adultos mayores en atención primaria (INTERLACE)
Avanzando la excelencia diagnóstica para adultos mayores a través de la inteligencia colectiva y el aprendizaje por imitación
Older adults commonly experience diagnostic errors that may lead to direct harms and increased healthcare costs. Older adults are especially at risk because of higher rates of comorbidity burden, medical complexity, frailty, and cognitive impairment. An artificial intelligence (AI) clinical decision support system (CDSS) offer a promising approach to promote diagnostic excellence for older adults.
The purpose of this study is to assess the acceptability and feasibility of a new AI CDSS for older adults in primary care. The goal of this AI CDSS is to provide diagnostic support during primary care visits (i.e., help make timely and accurate diagnoses) and support communication amongst patients, doctors, and caregivers about the patient's health.
In this study, participants will use the AI CDSS in a primary care visit and review its suggestions for diagnoses and tests. Afterwards, they will complete a feedback survey and interview where they share their thoughts about and experience using the AI CDSS.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Alyssa M Sliwa, BA
- Número de teléfono: 215-746-3080
- Correo electrónico: alyssa.sliwa@pennmedicine.upenn.edu
Copia de seguridad de contactos de estudio
- Nombre: Nicholas Bishop, BA
- Correo electrónico: nicholas.bishop@pennmedicine.upenn.edu
Ubicaciones de estudio
-
-
Pennsylvania
-
Philadephia, Pennsylvania, Estados Unidos, 19104
- University of Pennsylvania
-
Contacto:
- Clinical Research Coordinator
- Número de teléfono: 215-746-3080
- Correo electrónico: alyssa.sliwa@pennmedicine.upenn.edu
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
Clinicians
- Work in the University of Pennsylvania Health System
- Work in a primary care setting (i.e., Internal Medicine, Geriatric Medicine, Family Medicine, and Penn Primary Care)
- Actively treat adult patients who are 65 years old or older
Patients
- 65 years of age or older
- Have an upcoming encounter with a participating primary care clinician
- Indicate a new or worsening health concern that they wish to discuss at the upcoming encounter
Caregivers
- 18 years old or older
- Accompanying the participating patient during the encounter with the AI CDSS
- Identified by the patient as a caregiver
Exclusion Criteria:
An individual who meets any of the following criteria will be excluded from participation in this study:
- Under the age of 18 years old
- Unable to provide informed consent in the opinion of the investigator
- Has a "Research Do Not Contact" status in the electronic health record
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Diagnóstico
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Use of INTERLACE tool in primary care visit
All participants will be asked to use INTERLACE in their primary care visit. The tool will be presented on an handheld electronic device and may be used by patients, caregivers, and primary clinicians at each visit. First, the patient will input their current symptoms into INTERLACE. Then, using these symptoms, latest vital signs, and the patient's medical history, INTERLACE will make suggestions for diagnoses and tests. Patients, caregivers, and clinicians can view and discuss these suggestions together to arrive at a potential diagnosis. |
INTERLACE is an artificial intelligence-based clinical decision support tool. It uses a patient's medical history, vital signs, and current symptoms to make suggestions for diagnoses and tests. These suggestions can be considered and discussed amongst patients, caregivers, and clinicians during primary care visits to help find a good diagnosis for the patient's symptoms. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Feasibility of embedding the AI CDSS into a primary care visit
Periodo de tiempo: From enrollment to the end of the study interview, up to two weeks
|
Participants will complete a Feasibility of Intervention Measure (FIM) via feedback survey following the primary care visit. Responses are measured on a 5-point Likert scale. |
From enrollment to the end of the study interview, up to two weeks
|
|
Feasibility of embedding the AI CDSS into a primary care visit
Periodo de tiempo: From enrollment until the end of the study interview, up to two weeks
|
Feasibility will also be assessed through brief survey questions asking whether participants experienced any barriers to using INTERLACE, whether it was useful during the visit, and how long it was used (all measured on a 7-point Likert scale), as well as open-ended questions in a semi-structured interview. |
From enrollment until the end of the study interview, up to two weeks
|
|
Acceptability of embedding the AI CDSS into a primary care visit
Periodo de tiempo: From enrollment until the end of the study interview, up to two weeks
|
Participants will complete the Acceptability of Intervention Measure (AIM) via feedback survey after the primary care visit. Responses to the AIM are measured on a 5-point Likert scale. |
From enrollment until the end of the study interview, up to two weeks
|
|
Acceptability of embedding the AI CDSS into a primary care visit
Periodo de tiempo: From enrollment until the end of the study interview, up to two weeks
|
Participants will also complete a modified version of the Technology Acceptance model (TAM). Responses to the TAM are measured on a 7-point Likert scale. |
From enrollment until the end of the study interview, up to two weeks
|
|
Acceptability of embedding the AI CDSS into a primary care visit
Periodo de tiempo: From enrollment until the end of the study interview, up to two weeks
|
Participants will complete a Net Promoter Score assessing the likelihood that they would recommend the AI CDSS to others at the end of the survey. This will be measured on a 10-point scale. |
From enrollment until the end of the study interview, up to two weeks
|
|
Acceptability of embedding the AI CDSS into a primary care visit
Periodo de tiempo: From enrollment until the end of the study interview, up to two weeks
|
Acceptability will also be assessed through brief survey questions assessing whether INTERLACE caused distress (measured on a 7 point Likert scale), as well as open-ended questions in a semi-structured interview. |
From enrollment until the end of the study interview, up to two weeks
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Gary E Weissman, MD, MSPH, University of Pennsylvania
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Otros números de identificación del estudio
- 852952
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .